Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sera Prognostics Inc (SERA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SERA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 38.9% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 135.04M USD | Price to earnings Ratio - | 1Y Target Price 2.75 |
Price to earnings Ratio - | 1Y Target Price 2.75 | ||
Volume (30-day avg) 105485 | Beta 0.9 | 52 Weeks Range 3.33 - 12.36 | Updated Date 04/1/2025 |
52 Weeks Range 3.33 - 12.36 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.03 |
Earnings Date
Report Date 2025-03-20 | When - | Estimate -0.24 | Actual -0.25 |
Profitability
Profit Margin - | Operating Margin (TTM) -39262.5% |
Management Effectiveness
Return on Assets (TTM) -27.26% | Return on Equity (TTM) -55.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 93582543 | Price to Sales(TTM) 1753.77 |
Enterprise Value 93582543 | Price to Sales(TTM) 1753.77 | ||
Enterprise Value to Revenue 1215.36 | Enterprise Value to EBITDA -0.61 | Shares Outstanding 36695800 | Shares Floating 24854561 |
Shares Outstanding 36695800 | Shares Floating 24854561 | ||
Percent Insiders 12.91 | Percent Institutions 64.42 |
Analyst Ratings
Rating 5 | Target Price 2.75 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sera Prognostics Inc
Company Overview
History and Background
Sera Prognostics Inc. is a healthcare company focused on improving maternal and fetal health. Founded in 2006, the company develops and commercializes innovative diagnostic tests to predict preterm birth risk, aiming to reduce complications and improve outcomes.
Core Business Areas
- Preterm Birth Prediction: Developing and commercializing blood-based biomarker tests that predict the risk of spontaneous preterm birth.
Leadership and Structure
Sera Prognostics Inc. is led by a management team with expertise in diagnostics, obstetrics, and commercialization. The company operates with a focus on research and development, commercial operations, and clinical partnerships.
Top Products and Market Share
Key Offerings
- PreTRM Test: The PreTRM test is a blood-based proteomic test that predicts the risk of spontaneous preterm birth in singleton pregnancies. This test helps physicians to better manage at-risk pregnancies and improve outcomes. Market share is still developing. Competitors include traditional risk assessment methods and other experimental biomarker tests.
Market Dynamics
Industry Overview
The maternal health diagnostics market is growing due to increasing awareness of preterm birth risks and advances in biomarker technology. The industry faces challenges related to reimbursement, regulatory approval, and clinical adoption of new diagnostic tests.
Positioning
Sera Prognostics Inc. is positioned as a leader in preterm birth prediction with its PreTRM test. The company's competitive advantage lies in its proprietary biomarker technology and clinical validation studies.
Total Addressable Market (TAM)
The estimated TAM for preterm birth prediction is billions of dollars globally. Sera Prognostics Inc. is positioned to capture a significant share of this market through its innovative diagnostic solutions.
Upturn SWOT Analysis
Strengths
- Proprietary Biomarker Technology
- Clinically Validated PreTRM Test
- Focus on Maternal Health
- Established Clinical Partnerships
Weaknesses
- Limited Product Portfolio
- Dependence on PreTRM Test Sales
- Need for Increased Market Adoption
- Cash Burn Rate
Opportunities
- Expanding PreTRM Test Adoption
- Developing New Diagnostic Tests
- Entering New Geographic Markets
- Strategic Partnerships with Healthcare Providers
Threats
- Competition from Established Diagnostic Companies
- Reimbursement Challenges
- Regulatory Hurdles
- Changing Clinical Guidelines
Competitors and Market Share
Key Competitors
- ROST (Roster Health)
- PXDX (Prognosis Dx)
- NTRA (Natera Inc.)
Competitive Landscape
Sera Prognostics faces competition from established diagnostic companies and emerging biomarker startups. The company's competitive advantage lies in its proprietary technology and clinical validation studies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increasing adoption of the PreTRM test.
Future Projections: Future growth is projected to be driven by expanding market penetration and the development of new diagnostic tests.
Recent Initiatives: Recent initiatives include expanding commercial partnerships and investing in research and development.
Summary
Sera Prognostics is a promising company focused on maternal health diagnostics. The PreTRM test has the potential to improve outcomes for at-risk pregnancies. However, the company faces challenges related to reimbursement, market adoption, and competition and profitability. It needs to increase sales and improve its cost structure.
Similar Companies
ILMN
Illumina Inc
ILMN
Illumina Inc
NTRA
Natera Inc
NTRA
Natera Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Company Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary depending on the source. Actual results may differ from projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sera Prognostics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2021-07-15 | President, CEO & Director Ms. Evguenia Lindgardt M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 63 | Website https://www.sera.com |
Full time employees 63 | Website https://www.sera.com | ||
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.